Form 10-Q Apellis Pharmaceuticals, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
JPMorgan Take-Aways on Apellis Pharmaceuticals (APLS) Earnings
May 7, 2024 7:59 AM EDTJPMorgan analyst Anupam Rama reiterated an Overweight rating and $79.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "The quarter was highlighted by a 1Q24 beat for Syfovre, though we suspect the call will largely focus on near-term GA market dynamics post... More
